{
    "status": "ok",
    "totalResults": 35,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "DelveInsight Business Research LLP",
            "title": "Leptomeningeal Metastases Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2025\u20132034) | DelveInsight",
            "description": "The leptomeningeal metastases market is projected to grow steadily due to rising cancer incidence and the increasing prevalence of central nervous system complications in advanced malignancies. Additionally, the expected launch of therapies such as Rhenium-18\u2026",
            "url": "https://www.globenewswire.com/news-release/2025/09/09/3147250/0/en/Leptomeningeal-Metastases-Market-to-Exhibit-Growth-at-a-Paltry-CAGR-of-1-9-During-the-Forecast-Period-2025-2034-DelveInsight.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
            "publishedAt": "2025-09-09T17:00:00Z",
            "content": "New York, USA, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leptomeningeal Metastases Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (20252034) | DelveInsight\r\nThe leptomeningeal \u2026 [+19910 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "BusinessLine"
            },
            "author": "ANI",
            "title": "Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: Report",
            "description": "The report further noted that companies remain hopeful yet cautious around new growth avenues and product launches, which could help them offset the erosion in high-value launches",
            "url": "https://www.thehindubusinessline.com/economy/indian-pharma-sector-needs-price-hikes-site-and-ip-transfers-to-tackle-us-tariff-uncertainty-report/article70028449.ece",
            "urlToImage": "https://bl-i.thgim.com/public/incoming/6577zy/article70028462.ece/alternates/LANDSCAPE_1200/IMG_BL_-_27_09_2018_-_87_2_1_OMCE9LVM.jpg",
            "publishedAt": "2025-09-09T04:08:56Z",
            "content": "The Indian pharmaceutical industry requires price increases, site and intellectual property (IP) transfers to deal with the prevailing uncertainty in the sector amid US tariffs, according to a report\u2026 [+2507 chars]"
        },
        {
            "source": {
                "id": "the-times-of-india",
                "name": "The Times of India"
            },
            "author": "ANI",
            "title": "Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: Report",
            "description": "A Systematix Research report indicates the Indian pharmaceutical industry is navigating uncertainty due to US tariffs, necessitating price increases, site transfers, and IP transfers. While raw material prices stabilize and companies explore new growth avenue\u2026",
            "url": "https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-sector-needs-price-hikes-site-and-ip-transfers-to-tackle-us-tariff-uncertainty-report/articleshow/123777518.cms",
            "urlToImage": "https://img.etimg.com/thumb/msid-123777527,width-1200,height-630,imgsize-14706,overlay-economictimes/articleshow.jpg",
            "publishedAt": "2025-09-09T03:51:49Z",
            "content": "The Indian pharmaceutical industry requires price increases, site and intellectual property (IP) transfers to deal with the prevailing uncertainty in the sector amid US tariffs, according to a report\u2026 [+2537 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Livemint"
            },
            "author": "list.metadata.agency",
            "title": "Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: Report",
            "description": "The Indian pharmaceutical industry requires price increases, site and intellectual property (IP) transfers to deal with the prevailing uncertainty in the sector amid US tariffs, according to a report by Systematix Research",
            "url": "https://www.livemint.com/companies/news/indian-pharma-sector-needs-price-hikes-site-and-ip-transfers-to-tackle-us-tariff-uncertainty-report-11757388205384.html",
            "urlToImage": "https://www.livemint.com/lm-img/img/2024/12/06/1600x900/company_1_1733464951182_1733464958176.png",
            "publishedAt": "2025-09-09T03:23:24Z",
            "content": "New Delhi [India], September 9 (ANI): The Indian pharmaceutical industry requires price increases, site and intellectual property (IP) transfers to deal with the prevailing uncertainty in the sector \u2026 [+2539 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Ieq Capital LLC Decreases Stock Holdings in Dr. Reddy\u2019s Laboratories Ltd $RDY",
            "description": "Ieq Capital LLC trimmed its holdings in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 20.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,440 shares of the com\u2026",
            "url": "https://www.etfdailynews.com/2025/09/08/ieq-capital-llc-decreases-stock-holdings-in-dr-reddys-laboratories-ltd-rdy/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/dr-reddys-laboratories-limited-logo-1200x675.png?v=20240202075321&w=240&h=240&zc=2",
            "publishedAt": "2025-09-08T07:44:54Z",
            "content": "Ieq Capital LLC trimmed its holdings in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 20.8% in the first quarter, according to its most recent disclosure with the Securities and \u2026 [+5102 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Livemint"
            },
            "author": "Priyanka Sharma",
            "title": "Now Sun Pharma, Lupin work on anti-obesity pill to cut costs, address jab aversion",
            "description": "Sun Pharma and Lupin pursue regulatory approval for oral weight-loss drugs, potentially reshaping treatment access.",
            "url": "https://www.livemint.com/companies/now-sun-pharma-lupin-work-on-anti-obesity-pill-to-cut-costs-address-jab-aversion-11757239385114.html",
            "urlToImage": "https://www.livemint.com/lm-img/img/2025/09/07/1600x900/SUN-PHARM-RESULTS--0_1757255629292_1757255644553.JPG",
            "publishedAt": "2025-09-08T00:30:12Z",
            "content": "New Delhi: In a move to address India's obesity crisis, two major pharmaceutical companiesSun Pharma Laboratories Ltd and Lupin Ltdare working to create an affordable anti-obesity pill, according to \u2026 [+4565 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Acetaminophen Market Trends and Forecasts, 2023-2024 & 2025-2033 | Rising OTC Demand, Wider Access to Essential Medicines, and Growth in Combination Therapies Drive Expansion",
            "description": "The global acetaminophen market is set to grow at a CAGR of 4.5% from 2025-2033, driven by continued demand for OTC pain relief and expanding access to essential medicines. Widely used across age groups for pain and fever, its usage in combination therapies a\u2026",
            "url": "https://www.globenewswire.com/news-release/2025/09/05/3145154/28124/en/Acetaminophen-Market-Trends-and-Forecasts-2023-2024-2025-2033-Rising-OTC-Demand-Wider-Access-to-Essential-Medicines-and-Growth-in-Combination-Therapies-Drive-Expansion.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2025-09-05T09:53:00Z",
            "content": "Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The \"Acetaminophen Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025\u2026 [+4561 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Raloxifene Hydrochloride Market Analysis Report 2025 | A $3.95 Billion Industry, Reaching $5.7 Billion by 2030 | Regional Healthcare and Supply Chain Trends",
            "description": "The raloxifene hydrochloride market offers opportunities through preventative health applications, particularly in women\u2019s health, with expanding relevance in cancer prevention and bone health. Market segmentation favors cost-effective generics and diverse re\u2026",
            "url": "https://www.globenewswire.com/news-release/2025/09/04/3144396/28124/en/Raloxifene-Hydrochloride-Market-Analysis-Report-2025-A-3-95-Billion-Industry-Reaching-5-7-Billion-by-2030-Regional-Healthcare-and-Supply-Chain-Trends.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2025-09-04T11:36:00Z",
            "content": "Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The \"Raloxifene Hydrochloride Market by Indication (Breast Cancer Risk Reduction, Osteoporosis Prevention), Type (Branded, Generic), Distribution Channel, E\u2026 [+8906 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Pazopanib Generics Market Analysis and Forecast 2025-2030: Regional Variances in Regulatory and Reimbursement Frameworks Demand Tailored Market Entry Strategies",
            "description": "Dublin, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The \"Pazopanib Generics Market by Application (Ovarian Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma), Dosage Form (Capsule, Injectable, Tablet), Route Of Administration, Distribution Channel, End User - Global F\u2026",
            "url": "https://www.globenewswire.com/news-release/2025/09/03/3143349/28124/en/Pazopanib-Generics-Market-Analysis-and-Forecast-2025-2030-Regional-Variances-in-Regulatory-and-Reimbursement-Frameworks-Demand-Tailored-Market-Entry-Strategies.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2025-09-03T08:23:00Z",
            "content": "Dublin, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The \"Pazopanib Generics Market by Application (Ovarian Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma), Dosage Form (Capsule, Injectable, Tablet), Route \u2026 [+6895 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Anastrozole APl Market Analysis and Growth Forecast Report 2025-2030 Featuring Profiles of Key Players and Innovations",
            "description": "The Anastrozole API market presents key opportunities through technological innovation, regulatory alignment, and strategic collaborations. Advanced manufacturing and green chemistry enhance efficiency and sustainability, while compliance with evolving regula\u2026",
            "url": "https://www.globenewswire.com/news-release/2025/09/03/3143348/28124/en/Anastrozole-APl-Market-Analysis-and-Growth-Forecast-Report-2025-2030-Featuring-Profiles-of-Key-Players-and-Innovations.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2025-09-03T08:20:00Z",
            "content": "Dublin, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The \"Anastrozole APl Market by Generic Status (Branded, Generic), Application (Breast Cancer Treatment, Gynecomastia), Distribution Channel, End User - Glob\u2026 [+8106 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Erlotinib Generics Market Trends and Business Opportunities 2025-2030 - Shift from Branded Erlotinib to Generics Boosts Competition, Access, and Pricing Strategies",
            "description": "Dublin, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The \"Erlotinib Generics Market by Application (Non Small Cell Lung Cancer, Pancreatic Cancer), Formulation (Tablet Strength), Distribution Channel, End User - Global Forecast 2025-2030\" has been added to ResearchAndM\u2026",
            "url": "https://www.globenewswire.com/news-release/2025/09/03/3143346/28124/en/Erlotinib-Generics-Market-Trends-and-Business-Opportunities-2025-2030-Shift-from-Branded-Erlotinib-to-Generics-Boosts-Competition-Access-and-Pricing-Strategies.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2025-09-03T08:15:00Z",
            "content": "Dublin, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The \"Erlotinib Generics Market by Application (Non Small Cell Lung Cancer, Pancreatic Cancer), Formulation (Tablet Strength), Distribution Channel, End User\u2026 [+7495 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Hsbc Holdings PLC Has $1.21 Million Position in Dr. Reddy\u2019s Laboratories Ltd $RDY",
            "description": "Hsbc Holdings PLC decreased its stake in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 19.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 91,560 shares of the company\u2019s stock after selling 21,50\u2026",
            "url": "https://www.etfdailynews.com/2025/08/30/hsbc-holdings-plc-has-1-21-million-position-in-dr-reddys-laboratories-ltd-rdy/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/dr-reddys-laboratories-limited-logo-1200x675.png?v=20240202075321&w=240&h=240&zc=2",
            "publishedAt": "2025-08-30T08:52:58Z",
            "content": "Hsbc Holdings PLC decreased its stake in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 19.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm ow\u2026 [+5319 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "SNS Insider pvt ltd",
            "title": "Antiemetics Drugs Market to Hit USD 11.69 Billion by 2032, Driven by Rising Cancer Cases, Chemotherapy Demand, and Breakthrough Formulations \u2013 SNS Insider",
            "description": "SNS Insider Projects U.S. Antiemetics Drugs Market to Surpass USD 3.56 Billion by 2032, Capturing Strong Share Amid Growth in Oncology Care and Gastrointestinal Treatments. SNS Insider Projects U.S. Antiemetics Drugs Market to Surpass USD 3.56 Billion by 2032\u2026",
            "url": "https://www.globenewswire.com/news-release/2025/08/29/3141515/0/en/Antiemetics-Drugs-Market-to-Hit-USD-11-69-Billion-by-2032-Driven-by-Rising-Cancer-Cases-Chemotherapy-Demand-and-Breakthrough-Formulations-SNS-Insider.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/d6272c2e-d204-41b8-b545-a6e2e24f85c2",
            "publishedAt": "2025-08-29T13:30:00Z",
            "content": "Austin, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Antiemetics Drugs Market Size &amp; Growth Analysis\r\nAccording to SNS Insider, the global Antiemetics Drugs Market was valued at USD 6.73 billion in 2023 and\u2026 [+10025 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Wellington Management Group LLP Lowers Stake in Dr. Reddy\u2019s Laboratories Ltd $RDY",
            "description": "Wellington Management Group LLP cut its holdings in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 27.7% during the first quarter, Holdings Channel.com reports. The fund owned 648,060 shares of the company\u2019s stock after selling 248,105 sha\u2026",
            "url": "https://www.etfdailynews.com/2025/08/29/wellington-management-group-llp-lowers-stake-in-dr-reddys-laboratories-ltd-rdy/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/dr-reddys-laboratories-limited-logo-1200x675.png?v=20240202075321&w=240&h=240&zc=2",
            "publishedAt": "2025-08-29T07:55:02Z",
            "content": "Wellington Management Group LLP cut its holdings in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 27.7% during the first quarter, Holdings Channel.com reports. The fund owned 648\u2026 [+5499 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Research and Markets",
            "title": "Corneal Ulcer Market Analysis and Forecasts 2023-2025 & 2025-2035 | Surging Demand for Advanced Therapies Amid Rising Infection Rates, Innovative Drug Delivery Solutions Enhance Treatment Adherence",
            "description": "The global corneal ulcer treatment market is expanding rapidly, driven by the rising prevalence of corneal infections, improvements in pharmacological and regenerative therapies, and growing awareness about the condition. Corneal ulcers, caused by bacterial, \u2026",
            "url": "https://www.globenewswire.com/news-release/2025/08/28/3140592/28124/en/Corneal-Ulcer-Market-Analysis-and-Forecasts-2023-2025-2025-2035-Surging-Demand-for-Advanced-Therapies-Amid-Rising-Infection-Rates-Innovative-Drug-Delivery-Solutions-Enhance-Treatme.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7",
            "publishedAt": "2025-08-28T09:24:00Z",
            "content": "Dublin, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The \"Corneal Ulcer Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035\" report has been added to Resea\u2026 [+7398 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "BusinessLine"
            },
            "author": "KS Badri Narayanan",
            "title": "Key triggers for these three pharma stocks - Dr Reddy\u2019s Lab, Cipla, Biocon",
            "description": "Dr Reddy's Labs gets stay on tax reassessment, Cipla recalls asthma medication, Biocon gets FDA approval for Sitagliptin tablets.",
            "url": "https://www.thehindubusinessline.com/markets/key-triggers-for-these-three-pharma-stocks-dr-reddys-lab-cipla-biocon/article69983032.ece",
            "urlToImage": "https://bl-i.thgim.com/public/incoming/r2fe1n/article69910824.ece/alternates/LANDSCAPE_1200/IMG_iStock-539372506_2_1_TVCKPQU5.jpg",
            "publishedAt": "2025-08-28T01:29:54Z",
            "content": "Dr Reddys Laboratories has received an interim stay from the Telangana High Court on income tax reassessment proceedings related to its merger with Dr. Reddys Holding Ltd.\u00a0Dr Reddys Laboratories on S\u2026 [+1044 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Economictimes.com"
            },
            "author": "iStock",
            "title": "Nomura backs ICICI Bank, Infosys, 25 more stocks for long-term gains despite muted Q1, US tariff worries",
            "description": "Nomura suggests investing in twenty-seven stocks across sectors. These include ICICI Bank and Infosys. The brokerage anticipates long-term gains despite concerns about US tariffs. They are positive on financials, consumer goods, and autos. Mahindra & Mahindra\u2026",
            "url": "https://m.economictimes.com/markets/stocks/news/nomura-backs-icici-bank-infosys-25-more-stocks-for-long-term-gains-despite-muted-q1-us-tariff-worries/solid-bets/slideshow/123538979.cms",
            "urlToImage": "https://img.etimg.com/thumb/msid-123538979,width-1070,height-580,overlay-etmarkets/slideshow.jpg",
            "publishedAt": "2025-08-27T05:10:05Z",
            "content": "Aug 27, 2025, 10:49:25 AM IST\r\nJapanese brokerage Nomura has released its latest India equity strategy following muted Q1 earnings, flagging downside risks from US tariffs and sector-specific headwin\u2026 [+3885 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Ndtvprofit.com"
            },
            "author": "Pti",
            "title": "Dr Reddy's Expects New GST Framework To Address Critical Issues Impacting Pharma Sector",
            "description": "Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry.",
            "url": "https://www.ndtvprofit.com/business/dr-reddys-expects-new-gst-framework-to-address-critical-issues-impacting-pharma-sector",
            "urlToImage": "https://media.assettype.com/bloombergquint%2F2023-12%2F48f76266-e613-4b20-8138-52ebcf77c9d9%2FDr__Reddy_s_Laboratories_X.jfif?rect=0%2C0%2C1600%2C840&w=1200&auto=format%2Ccompress&ogImage=true",
            "publishedAt": "2025-08-26T22:02:16Z",
            "content": "However, applying a 5% rate to low-margin consumables like syringes, catheters and IV sets would worsen the inverted duty structure, increasing costs for Indian manufacturers and making imports cheap\u2026 [+144 chars]"
        },
        {
            "source": {
                "id": "the-times-of-india",
                "name": "The Times of India"
            },
            "author": "PTI",
            "title": "Dr Reddy's expects new GST framework to address critical issues impacting pharma sector",
            "description": "Dr Reddy's Laboratories anticipates that the new Goods and Services Tax structure will address existing challenges. It will also create a rationalised tax framework for the pharmaceutical sector. The Association of Indian Medical Device Industry seeks to reta\u2026",
            "url": "https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-expects-new-gst-framework-to-address-critical-issues-impacting-pharma-sector/articleshow/123527800.cms",
            "urlToImage": "https://img.etimg.com/thumb/msid-123527874,width-1200,height-630,imgsize-45632,overlay-economictimes/articleshow.jpg",
            "publishedAt": "2025-08-26T13:54:34Z",
            "content": "Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmace\u2026 [+2239 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "BusinessLine"
            },
            "author": "BL Hyderabad Bureau",
            "title": "Optimistic on GST reforms for\u00a0pharmaceutical sector: Dr Reddy\u2019s Chairman Satish Reddy",
            "description": "Dr. Reddy's Chairman optimistic about forthcoming GST reforms benefiting pharmaceutical industry, enhancing affordability, accessibility, and global competitiveness of medicines.",
            "url": "https://www.thehindubusinessline.com/companies/optimistic-on-gst-reforms-for-pharmaceutical-sector-dr-reddys-chairman-satish-reddy/article69979067.ece",
            "urlToImage": "https://bl-i.thgim.com/public/news/8kix62/article69979079.ece/alternates/LANDSCAPE_1200/Satish%20Reddy%20Chairman%20Dr.%20Reddys%20Laboratories%20.jpg",
            "publishedAt": "2025-08-26T12:43:16Z",
            "content": "K Satish Reddy, Chairman, Dr Reddys Laboratories, on Tuesday expressed optimism on the Centre addressing critical concerns for the pharmaceutical industry in the\u00a0forthcoming GST reforms.\r\nWelcoming t\u2026 [+1449 chars]"
        },
        {
            "source": {
                "id": "the-times-of-india",
                "name": "The Times of India"
            },
            "author": "PTI",
            "title": "Dr Reddy's launches novel drug for chronic constipation management",
            "description": "Dr Reddy's Laboratories has introduced Colozo, a generic drug for chronic constipation in India. This medication, Linaclotide, is approved by the USFDA. It addresses chronic idiopathic constipation and irritable bowel syndrome. This launch strengthens Dr Redd\u2026",
            "url": "https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-launches-novel-drug-for-chronic-constipation-management/articleshow/123525611.cms",
            "urlToImage": "https://img.etimg.com/thumb/msid-123525620,width-1200,height-630,imgsize-1895753,overlay-economictimes/articleshow.jpg",
            "publishedAt": "2025-08-26T11:52:57Z",
            "content": "Dr Reddy's Laboratories on Tuesday said it has launched a first-in-class generic medication for chronic constipation in the country.The drug firm has launched Linaclotide, a first-in-class guanylate \u2026 [+959 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Clinical Trials Arena"
            },
            "author": "GlobalData",
            "title": "FDA approves Coya Therapeutics\u2019 trial of COYA 302 for ALS",
            "description": "The therapy combines low-dose interleukin-2 and CTLA-4 Ig, intended for subcutaneous administration in ALS patients.",
            "url": "https://www.clinicaltrialsarena.com/news/fda-coya-therapeutics-trial-coya-302/",
            "urlToImage": "https://s.yimg.com/cv/apiv2/cv/apiv2/social/images/yahoo-finance-default-logo.png",
            "publishedAt": "2025-08-26T09:38:25Z",
            "content": "Coya Therapeutics has announced the acceptance by the US Food and Drug Administration (FDA) of its investigational new drug (IND) application for COYA 302, paving the way for a Phase II trial to trea\u2026 [+2259 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Dr. Reddy\u2019s Laboratories Ltd $RDY Shares Acquired by American Century Companies Inc.",
            "description": "American Century Companies Inc. lifted its holdings in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 6.0% in the first quarter, HoldingsChannel.com reports. The firm owned 914,473 shares of the company\u2019s stock after acquiring an additiona\u2026",
            "url": "https://www.etfdailynews.com/2025/08/26/dr-reddys-laboratories-ltd-rdy-shares-acquired-by-american-century-companies-inc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/dr-reddys-laboratories-limited-logo-1200x675.png?v=20240202075321&w=240&h=240&zc=2",
            "publishedAt": "2025-08-26T08:07:02Z",
            "content": "American Century Companies Inc. lifted its holdings in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 6.0% in the first quarter, HoldingsChannel.com reports. The firm owned 914,47\u2026 [+4503 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Livemint"
            },
            "author": "Jessica Jani",
            "title": "Mint Explainer | First Dr Reddy\u2019s, now Natco: Why Indian drugmakers are suing Novo Nordisk",
            "description": "As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The lawsuits could pave the way for cheaper generics, catering to India's vast population battling obesity.&nbsp;",
            "url": "https://www.livemint.com/companies/dr-reddy-s-natco-indian-drugmakers-novo-nordisk-patent-lawsuits-weight-loss-drugs-wegovy-ozempic-generic-drugs-11756124743725.html",
            "urlToImage": "https://www.livemint.com/lm-img/img/2025/08/25/1600x900/INDIA-WEGOVY-6_1751614661405_1751614669024_1756126241653.jpg",
            "publishedAt": "2025-08-25T13:03:18Z",
            "content": "Two Indian drugmakers have filed lawsuits against Danish drugmaker Novo Nordisk over its blockbuster weight-loss drug semaglutide, which is set to lose its patent in India in March 2026. With just ab\u2026 [+4426 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "PR Newswire UK"
            },
            "author": null,
            "title": "Biosimilars Market to Surpass US$ 171.79 Billion by 2033 - Exclusive Report by DataM Intelligence",
            "description": "HYDERABAD, India, Aug. 22, 2025 /PRNewswire/ -- According to DataM Intelligence, the global biosimilars market was valued at US$ 22.58 billion in 2024 and is projected to reach US$ 171.79 billion by 2033, growing at a compound annual growth rate (CAGR) of 25.\u2026",
            "url": "https://www.prnewswire.co.uk/news-releases/biosimilars-market-to-surpass-us-171-79-billion-by-2033---exclusive-report-by-datam-intelligence-302536731.html",
            "urlToImage": "https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg?p=facebook",
            "publishedAt": "2025-08-22T14:16:00Z",
            "content": "HYDERABAD, India, Aug. 22, 2025 /PRNewswire/ -- According to DataM Intelligence, the global biosimilars market was valued at US$ 22.58 billion in 2024 and is projected to reach US$ 171.79 billion by \u2026 [+11451 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Deutsche Bank AG Trims Stock Holdings in Dr. Reddy\u2019s Laboratories Ltd $RDY",
            "description": "Deutsche Bank AG trimmed its stake in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 12.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 150,687 shares of the company\u2019s stock \u2026",
            "url": "https://www.etfdailynews.com/2025/08/22/deutsche-bank-ag-trims-stock-holdings-in-dr-reddys-laboratories-ltd-rdy/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/dr-reddys-laboratories-limited-logo-1200x675.png?v=20240202075321&w=240&h=240&zc=2",
            "publishedAt": "2025-08-22T07:40:57Z",
            "content": "Deutsche Bank AG trimmed its stake in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 12.2% during the first quarter, according to the company in its most recent 13F filing with th\u2026 [+4522 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Cetera Investment Advisers Sells 1,586 Shares of Dr. Reddy\u2019s Laboratories Ltd $RDY",
            "description": "Cetera Investment Advisers cut its stake in Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 7.7% in the 1st quarter, Holdings Channel.com reports. The fund owned 19,134 shares of the company\u2019s stock after selling 1,586 shares during the quarter. Cete\u2026",
            "url": "https://www.etfdailynews.com/2025/08/22/cetera-investment-advisers-sells-1586-shares-of-dr-reddys-laboratories-ltd-rdy/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/dr-reddys-laboratories-limited-logo-1200x675.png?v=20240202075321&w=240&h=240&zc=2",
            "publishedAt": "2025-08-22T07:08:46Z",
            "content": "Cetera Investment Advisers cut its stake in Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 7.7% in the 1st quarter, Holdings Channel.com reports. The fund owned 19,134 shares of the company\u2026 [+4606 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Analysts Set Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY) PT at $16.95",
            "description": "Shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Get Free Report) have earned an average rating of \u201cModerate Buy\u201d from the five ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendati\u2026",
            "url": "https://www.etfdailynews.com/2025/08/22/analysts-set-dr-reddys-laboratories-ltd-nyserdy-pt-at-16-95/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/dr-reddys-laboratories-limited-logo-1200x675.png?v=20240202075321&w=240&h=240&zc=2",
            "publishedAt": "2025-08-22T05:14:48Z",
            "content": "Shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Get Free Report) have earned an average rating of \u201cModerate Buy\u201d from the five ratings firms that are covering the stock, MarketBeat Ratings reports\u2026 [+4589 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Lokmattimes.com"
            },
            "author": "Ani",
            "title": "Indian stock market ends higher on hopes of GST rate cut, rises for 6th straight session - www.lokmattimes.com",
            "description": "Indian stock market ends higher on hopes of GST rate cut, rises for 6th straight session - Mumbai (Maharashtra) [India], August 21 : The Indian stock market on Thursday ended higher on the sixth consecutive session ... - Latest News. Find Breaking Headlines, \u2026",
            "url": "https://www.lokmattimes.com/business/indian-stock-market-ends-higher-on-hopes-of-gst-rate-cut-rises-for-6th-straight-session/",
            "urlToImage": "https://d3pc1xvrcw35tl.cloudfront.net/ln/feedImages/1200x900/ANI-20250821104809_202508.jpg",
            "publishedAt": "2025-08-22T02:15:20Z",
            "content": "Mumbai (Maharashtra) [India], August 21 : The Indian stock market on Thursday ended higher on the sixth consecutive session as investors' sentiments are optimistic due to the possible Goods and Servi\u2026 [+3095 chars]"
        },
        {
            "source": {
                "id": "the-times-of-india",
                "name": "The Times of India"
            },
            "author": "PTI",
            "title": "US IT firm Kyndryl to invest $2.25 billion in India over three years",
            "description": "Kyndryl will invest with a focus on talent development and setting up an AI lab in India. The company aims to modernise infrastructure, as well as support India's digital goals, including AI, cybersecurity, and IT modernisation.",
            "url": "https://economictimes.indiatimes.com/tech/information-tech/us-it-firm-kyndryl-to-invest-2-25-billion-in-india-over-three-years/articleshow/123438103.cms",
            "urlToImage": "https://img.etimg.com/thumb/width-1200,height-900,imgsize-29116,resizemode-75,msid-123438103/tech/information-tech/us-it-firm-kyndryl-to-invest-2-25-billion-in-india-over-three-years.jpg",
            "publishedAt": "2025-08-21T17:42:05Z",
            "content": "US-based IT firm Kyndryl plans to invest $2.25 billion, about Rs 19,600 crore, in India over the next three years with a focus on developing future-ready talent and establishing an AI laboratory, the\u2026 [+2298 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Connor Clark & Lunn Investment Management Ltd. Decreases Position in Dr. Reddy\u2019s Laboratories Ltd $RDY",
            "description": "Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 89.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 31,814 shares of the company\u2019s stock after selli\u2026",
            "url": "https://www.etfdailynews.com/2025/08/20/connor-clark-lunn-investment-management-ltd-decreases-position-in-dr-reddys-laboratories-ltd-rdy/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/dr-reddys-laboratories-limited-logo-1200x675.png?v=20240202075321&w=240&h=240&zc=2",
            "publishedAt": "2025-08-20T08:48:50Z",
            "content": "Connor Clark &amp; Lunn Investment Management Ltd. decreased its holdings in shares of Dr. Reddy\u2019s Laboratories Ltd (NYSE:RDY \u2013 Free Report) by 89.6% in the 1st quarter, Holdings Channel.com reports.\u2026 [+4486 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Extrovis AG",
            "title": "Extrovis AG and Dr. Reddy\u2019s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.",
            "description": "Extrovis AG and Dr. Reddy\u2019s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.......",
            "url": "https://www.globenewswire.com/news-release/2025/08/18/3135006/0/en/Extrovis-AG-and-Dr-Reddy-s-announce-the-launch-of-the-authorized-generic-of-CARAC-fluorouracil-cream-0-5-in-the-U-S.html",
            "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/3548ee13-bb6c-49b8-9af3-83d8a4509695",
            "publishedAt": "2025-08-18T12:16:00Z",
            "content": "Press Release\r\nExtrovis AG and Dr. Reddys announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.\r\nBaar, Switzerland; August 14, 2025\r\nExtrovis AG, a global phar\u2026 [+5147 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Critical Contrast: Dr. Reddy\u2019s Laboratories (NYSE:RDY) & Teva Pharmaceutical Industries (NYSE:TEVA)",
            "description": "Dr. Reddy\u2019s Laboratories (NYSE:RDY \u2013 Get Free Report) and Teva Pharmaceutical Industries (NYSE:TEVA \u2013 Get Free Report) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of the\u2026",
            "url": "https://www.etfdailynews.com/2025/08/17/critical-contrast-dr-reddys-laboratories-nyserdy-teva-pharmaceutical-industries-nyseteva/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/teva-pharmaceutical-industries-limited-logo-1200x675.png?v=20221109123024&w=240&h=240&zc=2",
            "publishedAt": "2025-08-17T07:55:07Z",
            "content": "Dr. Reddy\u2019s Laboratories (NYSE:RDY \u2013 Get Free Report) and Teva Pharmaceutical Industries (NYSE:TEVA \u2013 Get Free Report) are both large-cap medical companies, but which is the superior investment? We w\u2026 [+7203 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Livemint"
            },
            "author": "list.metadata.agency",
            "title": "Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost",
            "description": "Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research and development activities with the business representatives of the pharmaceutical industry.",
            "url": "https://www.livemint.com/companies/news/piyush-goyal-meets-pharma-industry-leaders-to-discuss-r-d-competitiveness-boost-11755225458917.html",
            "urlToImage": "https://www.livemint.com/lm-img/img/2024/12/06/1600x900/company_4_1733465206851_1733465215415.png",
            "publishedAt": "2025-08-15T02:37:38Z",
            "content": "New Delhi [India], August 15 (ANI): Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research and development activities with the bus\u2026 [+2052 chars]"
        }
    ]
}